MARKET INDEX
KOSPI5,001.65▼ 1.30%
KOSDAQ654.84▼ 1.20%
S&P 5007,323.63▼ 0.23%
NASDAQ24,429.89▲ 0.42%
USD/KRW1,330.62▼ 1.92 (-0.14%)
WTI Crude$81.86▼ 0.55%
BTC/USD$63,034▲ 0.07%
KOSPI5,001.65▼ 1.30%
KOSDAQ654.84▼ 1.20%
S&P 5007,323.63▼ 0.23%
NASDAQ24,429.89▲ 0.42%
USD/KRW1,330.62▼ 1.92 (-0.14%)
WTI Crude$81.86▼ 0.55%
BTC/USD$63,034▲ 0.07%
헤더 좌
헤더 우
BREAKING
MARKET Times 공식 배너

Alteogen Clears Regulatory Hurdle as MSD Wins All 14 Patent Challenges Against Halozyme

U.S. PTAB Rejects Patentability of Final Two Claims, Stalling Halozyme's PH20 Variant Patents Keytruda SC Sales Surge 79%; Competitor Ivonescimab Faces U.S. Regulatory Setback Merck (MSD), which utilizes Alteogen's subcu

Alteogen Clears Regulatory Hurdle as MSD Wins All 14 Patent Challenges Against Halozyme
MTIMES Archive / Photo

U.S. PTAB Rejects Patentability of Final Two Claims, Stalling Halozyme's PH20 Variant Patents

Keytruda SC Sales Surge 79%; Competitor Ivonescimab Faces U.S. Regulatory Setback

Merck (MSD), which utilizes Alteogen's subcutaneous injection conversion technology, has emerged victorious in all 14 patent invalidation proceedings against Halozyme in the United States. With the U.S. Patent Trial and Appeal Board (PTAB) consistently ruling that the claims related to Halozyme's PH20 variants lack patentability, the legal burden surrounding the U.S. commercialization of Keytruda SC has been significantly alleviated. As MSD secures a favorable outcome in this months-long patent dispute, positive momentum is expected for the commercialization of Alteogen's core technology, ALT-B4.


Sweeping Victory in 14 U.S. Patent Trials; Halozyme's Broad Claims Checked


According to the U.S. Patent and Trademark Office (USPTO) PTAB on the 19th, final written decisions were issued on the 18th (local time) for two Post-Grant Review (PGR) proceedings initiated by MSD against Halozyme, declaring all challenged claims unpatentable.

The decisions concerned U.S. Patent Nos. 12,077,791 and 12,195,773, both of which relate to Halozyme's subcutaneous injection conversion technology, ENHANZE (MDASE).

This brings the total to 14 out of 14 PGR proceedings initiated by MSD where Halozyme's patent claims were found to be unpatentable. The favorable rulings, which began in May, continued through September, October, and early this month, culminating in the final two decisions.

The core of the dispute lies in the scope of the technical rights claimed by Halozyme. Both Alteogen's ALT-B4 and Halozyme's ENHANZE are based on the human hyaluronidase PH20 variant, which facilitates subcutaneous drug delivery. While Halozyme had secured broad patents regarding PH20 variants and associated delivery technologies, MSD argued that it was difficult to justify exclusive rights over the entire range of variants based solely on the evidence provided in the patent specifications.

The PTAB determined in previous rulings that Halozyme's limited experimental data on certain PH20 variants was insufficient to support such broad patent claims, citing failures to meet U.S. patent law requirements for written description and enablement. With all 14 proceedings resulting in the rejection of patentability, Halozyme's attempts to assert broad patent rights in the U.S. have faced repeated setbacks.

While this decision strengthens MSD's legal position against potential patent infringement litigation, the possibility of appeals and separate infringement lawsuits remains. In Europe, MSD has appealed a German court's injunction against the sale of Keytruda SC, with an appellate hearing scheduled for the 19th.

20261119_PTAB14.PNGKeytruda SC Sales Surge; Expansion of ALT-B4 Commercialization


MSD's legal victory coincides with the rapid growth of Keytruda SC sales. MSD developed the subcutaneous version of its intravenous (IV) immunotherapy, Keytruda, using Alteogen's ALT-B4, and has been marketing the product since receiving U.S. FDA approval last September.

Keytruda SC recorded $830 million in sales for the third quarter, a roughly 79% increase from the $463 million reported in the previous quarter. Cumulative sales for the first three quarters reached $1.42 billion. Alteogen also posted strong results, with third-quarter revenue of 119.8 billion KRW and an operating profit of 78.9 billion KRW, driven by sales milestones and technology export income. Revenue from technology services, including ALT-B4, accounted for approximately 111.5 billion KRW, or 93% of total revenue.

As Keytruda's commercialization expands, its potential competitor, ivonescimab, has hit a regulatory wall in the U.S. On the 13th, the FDA issued a Complete Response Letter (CRL) to Summit Therapeutics regarding its PD-1/VEGF bispecific antibody, ivonescimab. The FDA determined that the clinical data, which relied heavily on Chinese patients, was insufficient to evaluate therapeutic efficacy for U.S. patients, and that the improvement in overall survival in combination therapy for EGFR-mutated non-small cell lung cancer was not statistically proven.

With ivonescimab requiring additional clinical evidence to enter the U.S. market, MSD is aggressively pushing for the conversion and expansion of Keytruda SC. As MSD continues its winning streak in U.S. patent trials, Keytruda SC's quarterly sales have surpassed $800 million, creating a favorable environment for Alteogen to alleviate patent-related burdens and accelerate the commercial success of its core technology.

MARKET Times

MTIMES Global Editorial Statement

This analysis is provided for international business intelligence and informational purposes only. It does not constitute investment advice or a solicitation to buy or sell securities. For inquiries regarding licensing or syndication, please contact [email protected].

← More in CorporateBack to Top ↑

Related Market & Corporate Intelligence

The Robotaxi Arms Race: Can Waymo Maintain Its Lead Amid Safety Hurdles?The Robotaxi Arms Race: Can Waymo Maintain Its Lead Amid Safety Hurdles?Fed Minutes Reveal Consensus for Further Hikes; Wall Street Divided on January OutlookFed Minutes Reveal Consensus for Further Hikes; Wall Street Divided on January OutlookForeigners sell, individuals buy... credit-line loans 44 trillion, forced margin liquidation increases 3 timesForeigners sell, individuals buy... credit-line loans 44 trillion, forced margin liquidation increases 3 timesSamsung and SK Hynix Face Antitrust Scrutiny in U.S. Over DRAM Supply StrategiesSamsung and SK Hynix Face Antitrust Scrutiny in U.S. Over DRAM Supply Strategies
HomeTOP10AlmatenPicksCorpAlgiten